钠-葡萄糖协同转运蛋白2抑制剂与胰高血糖素样肽-1受体激动剂在伴或不伴心房颤动的糖尿病患者中的临床结局比较
基于台湾全民健康保险研究数据库的全国性回顾性队列研究,纳入2型糖尿病伴或不伴心房颤动患者,比较钠-葡萄糖协同转运蛋白2抑制剂(SGLT2i)与胰高血糖素样肽-1受体激动剂(GLP-1RA)的临床结局。在心房颤动队列中,SGLT2i与较低的心力衰竭住院风险相关(HR 0.48,95%CI 0.36-0.66),且复合肾脏结局风险亦较低(HR 0.47,95%CI 0.23-0.96);主要不良心血管事件和全因死亡风险无显著差异。作者提出,对于糖尿病合并心房颤动这一高危人群,SGLT2i是否应作为优于GLP-1RA的首选治疗需进一步研究。
要点
- 在心房颤动队列中,SGLT2i组心力衰竭住院发生率为2.32例/100人年,GLP-1RA组为4.74例/100人年,HR 0.48(95%CI 0.36-0.66)。
- 复合肾脏结局风险在心房颤动队列(HR 0.47,95%CI 0.23-0.96)和非心房颤动队列(HR 0.53,95%CI 0.43-0.64)中均较低。
- 主要不良心血管事件和全因死亡风险在两组间无显著差异。
核心结论
- 在2型糖尿病合并心房颤动的患者中,SGLT2i相比GLP-1RA与较低的心力衰竭住院和复合肾脏结局风险相关,主要不良心血管事件和全因死亡风险无显著差异。
- 作者认为,对于糖尿病合并心房颤动这一高危人群,SGLT2i是否应作为优于GLP-1RA的首选治疗需进一步研究。
研究设计与样本
- 全国性回顾性队列研究,数据来源于台湾全民健康保险研究数据库。
- 纳入2016年5月1日至2019年12月31日期间接受SGLT2i或GLP-1RA治疗的2型糖尿病患者:不伴心房颤动者分别为344 392例和31 351例,伴心房颤动者分别为11 462例和816例。
- 随访自药物索引日期开始,至研究事件发生、索引药物停用或研究期结束(2020年12月31日)为止,以先发生者为准。
- 采用倾向评分稳定权重平衡两组协变量。
主要发现
- 合并心房颤动患者的所有研究结局发生率均远高于不伴心房颤动者。
- 心房颤动队列中,SGLT2i组心力衰竭住院发生率为2.32例/100人年,GLP-1RA组为4.74例/100人年,HR 0.48(95%CI 0.36-0.66);非心房颤动队列未见获益(同质性P<0.01)。
- 复合肾脏结局:心房颤动队列SGLT2i组0.38例/100人年 vs GLP-1RA组0.79例/100人年,HR 0.47(95%CI 0.23-0.96);非心房颤动队列SGLT2i组0.09例/100人年 vs GLP-1RA组0.18例/100人年,HR 0.53(95%CI 0.43-0.64)。
- 心房颤动和非心房颤动队列中,SGLT2i与GLP-1RA相比,主要不良心血管事件和全因死亡风险均无显著差异。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CONTEXT: The coexistence of diabetes mellitus and atrial fibrillation (AF) is associated with substantial risks of adverse cardiovascular events. OBJECTIVE: The relevant outcomes associated with the use of a sodium-glucose cotransporter-2 inhibitor (SGLT2i) vs glucagon-like peptide-1 receptor agonists (GLP-1RAs) among patients with type 2 diabetes (T2D) with/without concomitant AF remain unknown. METHODS: In this nationwide retrospective cohort study from the Taiwan National Health Insurance Research Database, there were 344 392 and 31 351 patients with T2D without AF, and 11 462 and 816 T2D patients with AF treated with SGLT2is and GLP-1RAs, respectively, from May 1, 2016, to December 31, 2019. Patients were followed from the drug index date until the occurrence of study events, discontinuation of the index drug, or the end of the study period (December 31, 2020), whichever occurred first. We used propensity score-stabilized weight to balance covariates across the 2 medication groups. RESULTS: The incidence rate of all study outcomes in patients with concomitant AF was much higher than in those without concomitant AF. For the AF cohort, SGLT2i vs GLP-1RA was associated with a lower risk of hospitalization for heart failure (HF) (2.32 vs 4.74 events per 100 person-years; hazard ratio [HR] 0.48, 95% CI 0.36-0.66), with no benefit seen for the non-AF cohort (P for homogeneity < .01). SGLT2i vs GLP-1RA was associated with a lower risk of composite kidney outcomes both in the AF (0.38 vs 0.79 events per 100 person-years; HR 0.47; 95% CI 0.23-0.96) and the non-AF cohorts (0.09 vs 0.18 events per 100 person-years; HR 0.53; 95% CI 0.43-0.64). There were no significant differences in the risk of major adverse cardiovascular events and all-cause mortality in those who received SGLT2i compared with GLP-1RA for the AF or non-AF cohorts. CONCLUSION: Considering the high risk of developing HF and/or high prevalence of concomitant HF in patients with concomitant diabetes and AF, whether SGLT2is should be the preferred treatment to GLP-1RAs for such a high-risk population requires further investigation.
引用
- Chan YH, Chao TF, Chen SW, et al. SGLT2 Inhibitors vs GLP-1 Receptor Agonists and Clinical Outcomes in Patients With Diabetes With/Without Atrial Fibrillation. J Clin Endocrinol Metab. 2024. PMID: 38466894. doi:10.1210/clinem/dgae157
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。